ClinicalTrials.gg
RecruitingNCT04800484AFOHeelUpdated Oct 21, 2026

The Effects of AFO Heel Height and Stiffness on Gait

An interventional study of Tall Soft and Tall Firm in Musculoskeletal Injury, Musculoskeletal Diseases and Peripheral Nervous System Diseases, sponsored by University of Iowa. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by University of Iowa · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Nov 2019, registered Mar 2021).
  • Started Nov 2019; still recruiting 7 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The proposed study evaluates the effect of ankle foot orthosis (AFO) heel height and stiffness on the forces and motion of the lower limb during over-ground walking in individuals who use an AFO for daily walking. Previous studies suggest that heel height and stiffness effect limb loading, but these data and the analysis techniques applied are limited. In this study, heel cushions with different height and stiffness's (4 conditions) will be placed in participants shoes and they will walk at controlled and self-selected speeds. Participants will also walk with their AFO as configured prior to enrollment, and with no AFO if possible. The proposed study will provide evidence that can be used by clinicians and researchers to align braces that most effectively improve function during every-day walking.

Read the detailed description

In this study the investigators to evaluate the effect of ankle foot orthosis (AFO) heel height and stiffness on the forces and motion of the lower limb during over-ground walking in individuals who use an AFO for daily walking. Previous studies suggest that heel height and stiffness effect limb loading, but these data and the analysis techniques applied are limited.

Two groups of subjects with impairments below the knee, that result in functional deficits and require daily AFO use, will be recruited for this study. The first group will have unilateral deficits associated with musculoskeletal injury or disease (Group 1), and the second group will have bilateral or unilateral deficits associated with peripheral nervous system disease (Group 2).

Lower limb forces and body motion will be assessed using computerized motion capture and force plates in the floor, as individuals walk over-ground. Small reflective markers placed on the participant's skin and force measuring plates in the floor will be used. Participants will walk with their clinically provided AFO, with added heel cushions of two different heights and stiffness's (4 conditions) at a controlled velocity and self-selected velocity. If able, they will walk without their AFO at a self-selected pace. Participants will be asked to provide information regarding their health condition and opinions of the conditions tested.

02

Conditions studied

  • Musculoskeletal Injury
  • Musculoskeletal Diseases
  • Peripheral Nervous System Diseases

Keywords

  • Gait Analysis
  • Ankle Foot Orthosis
  • Biomechanics
03

In context

Musculoskeletal Diseases

753 studies on the registry are indexed under Musculoskeletal Diseases; 164 are open to participants now.

This study's planned enrollment of 40 is below the median of 76 across 519 interventional studies indexed under Musculoskeletal Diseases.

Browse Musculoskeletal Diseases studies →

Lead sponsor

University of Iowa is the lead sponsor of 279 studies on the registry; 32 are open to participants now.

Of its 45 completed or terminated interventional studies of FDA-regulated products, 40 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

GROUP 1 Patient Inclusion criteria

  • Ages: 18-70
  • Daily AFO use to address unilateral, below knee functional deficits that result from limb injury or musculoskeletal disease (e.g. fracture, muscle and/or nerve injury, ankle arthritis)
  • Greater than 2 weeks using their current AFO
  • Ability to walk 50 feet without use of an assistive device (Cane, crutch, etc.)
  • Ability to walk at a slow to moderate pace
  • AFO fits into traditional footwear
  • Able to read and write in English and provide written

GROUP 1 Patient Exclusion criteria

  • Pain > 6/10 while walking during testing or an increase in pain during testing of > 2/10.
  • Central Nervous System disorder or disease (e.g. Stroke, Cerebral Palsy, Spinal Cord Injury, or other conditions that result in lower limb spasticity).
  • Disorder or disease that affects peripheral nerve function (e.g. diabetes, Charcot Marie Tooth).
  • Limited contralateral lower limb function due to injury or neurological/musculoskeletal disorder.
  • Use of a hinged/articulating AFO (e.g. Plantar flexion stop, Dorsiflexion assist/stop, free motion), Charcot Restraint Orthotic Walker (CROW) boot, AFOs that restrict all motion in the ankle and foot.
  • Use of an AFO that crosses the knee (Knee brace)
  • Insufficient space in shoe to accommodate the tallest heel wedge and their AFO
  • Visual or hearing impairments that limit walking ability or could limit the ability to comply with instructions given during testing
  • Pregnancy - Per participant self-report. Due the expected small number of pregnant individuals, and resulting inability to account for its effect on resulting outcomes participants will be withdrawn from the study.
  • > 40.

GROUP 2 Patient Inclusion Criteria

  • Ages: 18-70
  • Daily AFO use to address below knee functional deficits that result from disease involving the peripheral nervous system (e.g. Charcot Marie Tooth, Multiple Sclerosis, diabetes)
  • Greater than 2 weeks using their current AFO (unilateral or bilateral)
  • Ability to walk 50 feet without use of an assistive device (Cane, crutch, etc.)
  • AFO fits into traditional footwear
  • Ability to walk at a slow to moderate pace
  • Able to read and write in English and provide written informed consent

GROUP 2 Patient Exclusion Criteria

  • Pain > 6/10 while walking or an increase in pain during testing of > 2/10
  • Central Nervous System disorder or disease (e.g. Stroke, Cerebral Palsy, Spinal Cord Injury, or other conditions that result in lower limb spasticity)
  • Limited function due to limb injury (e.g. fracture, muscle and/or nerve injury)
  • Use of a hinged/articulating AFO (e.g. Plantar flexion stop, Dorsiflexion assist/stop, free motion), Charcot Restraint Orthotic Walker (CROW) boot, AFOs that restrict all motion in the ankle and foot.
  • Use of an AFO that crosses the knee (Knee brace)
  • Insufficient space in shoe to accommodate the tallest heel wedge and their AFO
  • Visual or hearing impairment that limit walking ability or limit the ability to comply with instructions given during testing
  • Pregnancy - Per participant self-report. Due the expected small number of pregnant individuals, and resulting inability to account for its effect on resulting outcomes participants will be withdrawn from the study
  • Body Mass index > 40.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Arm 1:

    Testing Order: Clinical AFO, Tall Soft, Tall Firm, Short Soft, Short Firm, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 2:

    Testing Order: Clinical AFO, Tall Soft, Tall Firm, Short Firm, Short Soft, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 3:

    Testing Order: Clinical AFO, Tall Soft, Short Soft, Tall Firm, Short Firm, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 4:

    Testing Order: Clinical AFO, Tall Soft, Short Soft, Short Firm, Tall Firm, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 5:

    Testing Order: Clinical AFO, Tall Soft, Short Firm, Tall Firm, Short Soft, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 6:

    Testing Order: Clinical AFO, Tall Soft, Short Firm, Short Soft, Tall Firm, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 7:

    Testing Order: Clinical AFO, Tall Firm, Tall Soft, Short Soft, Short Firm, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 8:

    Testing Order: Clinical AFO, Tall Firm, Tall Soft, Short Firm, Short Soft, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 9:

    Testing Order: Clinical AFO, Tall Firm, Short Soft, Tall Soft, Short Firm, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 10:

    Testing Order: Clinical AFO, Tall Firm, Short Soft, Short Firm, Tall Soft, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 11:

    Testing Order: Clinical AFO, Tall Firm, Short Firm, Tall Soft, Short Soft, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 12:

    Testing Order: Clinical AFO, Tall Firm, Short Firm, Short Soft, Tall Soft, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 13:

    Testing Order: Clinical AFO, Short Soft, Tall Soft, Short Firm, Tall Firm, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 14:

    Testing Order: Clinical AFO, Short Soft, Tall Soft, Tall Firm, Short Firm, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 15:

    Testing Order: Clinical AFO, Short Soft, Tall Firm, Short Firm, Tall Soft, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 16:

    Testing Order: Clinical AFO, Short Soft, Tall Firm, Tall Soft, Short Firm, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 17:

    Testing Order: Clinical AFO, Short Soft, Short Firm, Tall Soft, Tall Firm, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 18:

    Testing Order: Clinical AFO, Short Soft, Short Firm, Tall Firm, Tall Soft, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 19:

    Testing Order: Clinical AFO, Short Firm, Tall Soft, Tall Firm, Short Soft, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 20:

    Testing Order: Clinical AFO, Short Firm, Tall Soft, Short Soft, Tall Firm, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 21:

    Testing Order: Clinical AFO, Short Firm, Tall Firm, Short Soft, Tall Soft, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 22:

    Testing Order: Clinical AFO, Short Firm, Tall Firm, Tall Soft, Short Soft, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 23:

    Testing Order: Clinical AFO, Short Firm, Short Soft, Tall Firm, Tall Soft, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

  • Experimental
    Arm 24:

    Testing Order: Clinical AFO, Short Firm, Short Soft, Tall Soft, Tall Firm, NoAFO

    Device: Tall Soft · Device: Tall Firm · Device: Short Soft · Device: Short Firm

Interventions

  • DeviceTall Soft

    Tall heel wedge made of soft foam

    Also known as: TS

  • DeviceTall Firm

    Tall heel wedge made of firm foam

    Also known as: TF

  • DeviceShort Soft

    Short heel wedge made of soft foam

    Also known as: SS

  • DeviceShort Firm

    Short heel wedge made of firm foam

    Also known as: SF

06

What researchers measure

Primary outcomes

  1. Center of pressure velocity timing

    Timing of peak center of pressure velocity (percent stance) during gait.

    Time frame: Baseline

  2. Center of pressure velocity magnitude

    Magnitude of peak center of pressure velocity (m/s) during gait.

    Time frame: Baseline

  3. Modified Socket Comfort Score (Comfort)

    Comfort scores range from 0 = most uncomfortable to 10 = most comfortable.

    Time frame: Baseline

  4. Modified Socket Comfort Score (Smoothness)

    Smoothness scores range from 0 = least smooth to 10 = most smooth.

    Time frame: Baseline

  5. Numerical Pain Rating Scale

    Pain will be assessed using a standard 11-point numerical pain rating scale, in which 0 = no pain and 10 = worst pain imaginable.

    Time frame: Baseline

  6. Participant wedge preference

    The participant will rank order their preference for their Clinical AFO, Tall Soft, Tall Firm, Short Soft, or Short Firm wedge on a questionnaire.

    Time frame: Baseline

Secondary outcomes

  1. Ankle Range of Motion

    Ankle range of motion (degrees) during gait.

    Time frame: Baseline

  2. Peak Ankle Moment

    Peak ankle moment (Nm/kg) during gait.

    Time frame: Baseline

  3. Peak Ankle Power

    Peak ankle power (W/kg) during gait.

    Time frame: Baseline

Other outcomes

  1. Activities-Specific Balance Confidence (ABC)

    The ABC provides a standardized evaluation of balance confidence across a range of common daily tasks.

    Time frame: Baseline

  2. PROMIS Patient reported outcomes for physical function

    The Patient Reported Outcome Information System (PROMIS) physical function Computer Adaptive Test (CAT) is a computerized assessment measuring physical function. It is scored using a T-score in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. In a given PROMIS domain, a T-score above 50 represents more of the measured variable than the population average.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2019 (actual). Primary completion is estimated for Jan 2027, 85 months after the start.

Of 251 non-industry interventional studies with no phase under Musculoskeletal Diseases, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 38. This study's planned 85 months is above that.

Counting every sponsor, half of 266 studies reached it within 16 months; a quarter within 6 and three quarters within 36.

Musculoskeletal Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2021
First posted
Mar 16, 2021
StartActual
Nov 7, 2019
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04800484
Lead sponsor
University of Iowa
Responsible party
Jason Wilken (Associate Professor, University of Iowa) — Principal investigator
First posted
Mar 16, 2021
Start date
Nov 7, 2019
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Jason M Wilken, PT, PhD
Contact
jason-wilken@uiowa.edu
319-335-6857
Kirsten M Anderson, PhD
Contact
kirsten-m-anderson@uiowa.edu
319-353-0431
Jason M Wilken, PT, PhD
principal investigator · University of Iowa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion